Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2

類似資料

• Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
  著者:: Helliwell, Philip S, 等
  出版事項: (2020)
• RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
  著者:: Yu. L. Korsakova, 等
  出版事項: (2015-04-01)
• Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
  著者:: Rahman, Proton, 等
  出版事項: (2016)
• Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
  著者:: Kavanaugh, Arthur, 等
  出版事項: (2015)
• Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
  著者:: Kavanaugh, Arthur, 等
  出版事項: (2014)